148 related articles for article (PubMed ID: 33082556)
21. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
[TBL] [Abstract][Full Text] [Related]
23. Gain of the short arm of chromosome 2 (2p gain) has a significant role in drug-resistant chronic lymphocytic leukemia.
Kostopoulou F; Gabillaud C; Chapiro E; Grange B; Tran J; Bouzy S; Degaud M; Ghamlouch H; Le Garff-Tavernier M; Maloum K; Choquet S; Leblond V; Gabarre J; Lavaud A; Morel V; Roos-Weil D; Uzunov M; Guieze R; Bernard OA; Susin SA; Tournilhac O; Nguyen-Khac F;
Cancer Med; 2019 Jun; 8(6):3131-3141. PubMed ID: 31066214
[TBL] [Abstract][Full Text] [Related]
24. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.
Wierzbinska JA; Toth R; Ishaque N; Rippe K; Mallm JP; Klett LC; Mertens D; Zenz T; Hielscher T; Seifert M; Küppers R; Assenov Y; Lutsik P; Stilgenbauer S; Roessner PM; Seiffert M; Byrd J; Oakes CC; Plass C; Lipka DB
Genome Med; 2020 Mar; 12(1):29. PubMed ID: 32188505
[TBL] [Abstract][Full Text] [Related]
25. Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact.
Mansouri L; Wierzbinska JA; Plass C; Rosenquist R
Semin Cancer Biol; 2018 Aug; 51():1-11. PubMed ID: 29427646
[TBL] [Abstract][Full Text] [Related]
26. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
27. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
[TBL] [Abstract][Full Text] [Related]
28. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
29. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.
Giacopelli B; Zhao Q; Ruppert AS; Agyeman A; Weigel C; Wu YZ; Gerber MM; Rabe KG; Larson MC; Lu J; Blachly JS; Rogers KA; Wierda WG; Brown JR; Rai KR; Keating M; Rassenti LZ; Kipps TJ; Zenz T; Shanafelt TD; Kay NE; Abruzzo LV; Coombes KR; Woyach JA; Byrd JC; Oakes CC
Blood; 2019 Aug; 134(8):688-698. PubMed ID: 31292113
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy.
Yosifov DY; Bloehdorn J; Döhner H; Lichter P; Stilgenbauer S; Mertens D
Sci Data; 2020 May; 7(1):133. PubMed ID: 32358561
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia.
Gaiti F; Chaligne R; Gu H; Brand RM; Kothen-Hill S; Schulman RC; Grigorev K; Risso D; Kim KT; Pastore A; Huang KY; Alonso A; Sheridan C; Omans ND; Biederstedt E; Clement K; Wang L; Felsenfeld JA; Bhavsar EB; Aryee MJ; Allan JN; Furman R; Gnirke A; Wu CJ; Meissner A; Landau DA
Nature; 2019 May; 569(7757):576-580. PubMed ID: 31092926
[TBL] [Abstract][Full Text] [Related]
32. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
33. Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications.
Kulis M; Martin-Subero JI
Br J Haematol; 2023 Feb; 200(3):280-290. PubMed ID: 36121003
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.
Pei L; Choi JH; Liu J; Lee EJ; McCarthy B; Wilson JM; Speir E; Awan F; Tae H; Arthur G; Schnabel JL; Taylor KH; Wang X; Xu D; Ding HF; Munn DH; Caldwell C; Shi H
Epigenetics; 2012 Jun; 7(6):567-78. PubMed ID: 22534504
[TBL] [Abstract][Full Text] [Related]
35. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.
Motiwala T; Majumder S; Kutay H; Smith DS; Neuberg DS; Lucas DM; Byrd JC; Grever M; Jacob ST
Clin Cancer Res; 2007 Jun; 13(11):3174-81. PubMed ID: 17545520
[TBL] [Abstract][Full Text] [Related]
36. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments.
Cahill N; Bergh AC; Kanduri M; Göransson-Kultima H; Mansouri L; Isaksson A; Ryan F; Smedby KE; Juliusson G; Sundström C; Rosén A; Rosenquist R
Leukemia; 2013 Jan; 27(1):150-8. PubMed ID: 22922567
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Blum KA; Liu Z; Lucas DM; Chen P; Xie Z; Baiocchi R; Benson DM; Devine SM; Jones J; Andritsos L; Flynn J; Plass C; Marcucci G; Chan KK; Grever MR; Byrd JC
Br J Haematol; 2010 Jul; 150(2):189-95. PubMed ID: 20456354
[TBL] [Abstract][Full Text] [Related]
38. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
39. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
[TBL] [Abstract][Full Text] [Related]
40. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
